NCT06710210View on ClinicalTrials.gov

Hybrid Percutaneous Coronary Intervention Combining a Bioresorbable Scaffold With Drug-coated Balloons Versus a Conventional Drug-eluting Stent-based Strategy in Patients With Long and Diffuse Coronary Artery Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Coronary Artery DiseaseDiffuse Coronary Artery DiseasePercutaneous Coronary Intervention (PCI)
Interventions
DEVICE

PCI with a bioresorbable scaffold and drug-coated balloon(s)

Hybrid PCI combining a magnesium-based sirolimus-eluting bioresorbable scaffold (Freesolve, Biotronik AG, Switzerland) and ≥1 paclitaxel-eluting drug-coated balloon(s) (Pantera Lux, Biotronik AG, Switzerland)

DEVICE

PCI with drug-eluting stent(s)

PCI with \>1 newer-generation drug-eluting stent (Orsiro Mission, Biotronik AG, Switzerland)

Trial Locations (1)

1205

Geneva University Hospitals, Geneva

Sponsors
All Listed Sponsors
collaborator

Clinical Trials Unit Bern (CTU)

UNKNOWN

lead

University Hospital, Geneva

OTHER